 | Peter Fellner, Chairman of the Board Born: 1943
Education: Ph.D. in molecular biology
Board member since October 2009
Principal occupation: Company Director
Employment history: CEO of Celltech Group Plc from 1990 to 2003, and its Chairman until 2004. CEO of Roche UK from 1986 to 1990. Also served as a Director of a number of other public companies.
Key position of trust: Chairman of Consort Medical Plc, Chairman of Optos Plc, Chairman of Vernalis Plc, Chairman of Astex Therapeutics Ltd, Director of UCB SA, Director of Evotec AG Number of shares held in Biotie |
 | Merja Karhapää
Born: 1962
Education: LL.M. (Helsinki University) and Postgraduate IPR Diploma (Bristol University)
Board member since April 2010
Principal occupation: Chief Legal Officer (CLO, Group Legal Affairs) and Company Secretary(since 2008)
Employment history: Sanoma Corporation since 2000 as Vice President, Group Legal Affairs. Vice President, Intellectual Capital of Danisco, Trademark Counsel and Assistant General Counsel of Cultor and Danisco in 1996-2000 and as Corporate Counsel of Sanoma(former Sanoma News) and Valmet.
Key positions of trust: Helsingin Sanomat Foundation deputy member, Market Court expert member (competition matters), Chairman of the Central Chamber of Commerce IPR Committee and Finnish IPR Forum, Confederation of Finnish Industries IPR Committee member, Confederation of Finnish Industries Law Committee member, Ministry of Education Copyright Commission member
Number of shares held in Biotie
|
 | Bernd Kastler
Born: 1949
Education: Doctorate in law in 1980 from the University of Giessen (Germany).
Board member since November 2008
Principal occupation: Company Director
Employment history: Co-founder and from 2002 until 2008 CEO of elbion NV. From 1989 until 2002 Member of the Executive Board of ASTA Medica AG, the pharmaceutical subsidiary of Degussa AG. His responsibilities included the fi nance and the human resources areas. Between 1979 and 1989 different positions at Degussa AG.
Key positions of trust: Kastler GmbH, controlled company and Managing Director: beloni Konsortial Gesellschaft Number of shares held in Biotie |
 | Pauli Marttila, Deputy Chairman of the Board
Born: 1958
Education: M.Sc. (Tech.)
Board member since March 2005
Principal occupation: Director, Business Development and Strategic Investments at Sitra, the Finnish Innovation Fund
Employment history: Sitra Ventures, Director 2006–2008, Sitra Life Sciences, Director 2005–2006. Sitra Life Sciences, Corporate Finance, Director 1999–2004. Neste Corp. (later Fortum Corp.), Management positions in several R&D and business operations since 1983, General Manager of New Developments business unit at Neste Chemicals in Finland 1996–1999. Neste Noptek Venture Capital Fund (Boston, USA), Manager 1993–1995. Finnish Consulate General (Los Angeles, USA), Assistant Attaché 1984–1985.
Key positions of trust: Odum Oy, Chairman of the Board of Directors. Mobidiag Oy, Chairman of the Board of Directors. Bio Fund I-III venture funds, Member of the investment committee. Next Wave Funds (New York, USA) and Apple Tree Partners II Fund (New York, USA), Member of the Advisory Board. Number of shares held in Biotie |
 | Riku Rautsola
Born: 1954
Education: Ph.D. (Econ.)
Board member since March 2004
Principal occupation: President and CEO, VIRxSYS Corporation since 2005
Employment history: General Management, Sales and Marketing, Operations, Manufacturing, Business Development and Research& Development positions in Denmark, Germany, the United States and China over 20 years. Borean Pharma, President and CEO 2003– 2004. Cosmix Molecular Biologicals, CEO 2001-2003. Accelerating Access, a public private initiative of the UN and the pharmaceutical industry, Founding member and Chairman 2000–2001. ”Free Nevirapine for the prevention of mother to child HIV transmission”, Founder 2001. Boehringer Ingelheim, Beiersdorf and Fresenius, diverse management positions.
Key positions of trust: VIRxSYS, Board
Number of shares held in Biotie |
 | Piet Serrure
Born: 1954
Education: M.Sc. (Econ.)
Board member since March 2004
Principal occupation: Becap Bvba, Managing Director since 2006
Employment history: Origo Management, Managing Director 2001–2006. Parnib (NIB Capital), Director and CEO until 2001. Benevent (venture capital company) 1985. Different positions at Du Pont de Nemours and Arthur Andersen. 1976–1985. European Private Equity and Venture Capital Association (EVCA), Member of the Board of Directors until 2004.
Key positions of trust: Europe Unlimited, Chairman of the Board of Directors. Member of the Board of Directors at Fin. Co, IPTE, Visys, Finalame, Wichard and Hybrigenics.
Number of shares held in Biotie |
| James S. Shannon
Born: 1956
Education: Doctor of Medicine
Board member since April 2010
Principal occupation: CEO and a director of Cerimon Pharmaceuticals and a director of Crucell, Xanodyne Pharmaceuticals Inc, Mannkind Corporation and Endocyte Inc
Employment history: Novartis Pharma from 1995 to 2008 most recently as Global Head, Pharma Development. Prior to this he was with Sterling research group from 1987 to 1994.
Key positions of trust: Number of shares held in Biotie ----
Updated May, 2010 |